Trial record 1 of 1 for:    medi-559
Previous Study | Return to List | Next Study

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children

This study has been completed.
Sponsor:
Information provided by:
MedImmune LLC
ClinicalTrials.gov Identifier:
NCT00767416
First received: October 3, 2008
Last updated: August 8, 2012
Last verified: August 2012
  Purpose

The primary objective of this study is to describe the 28-day post-final dose safety and tolerability of three doses of MEDI-559 at 10^5 FFU when administered to healthy RSV seronegative children 1 to <24 months of age.


Condition Intervention Phase
Healthy
Biological: MEDI-559
Other: Placebo
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, and Viral Shedding of MEDI-559, a Live Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus in Healthy 1 to <24 Month-Old Children

Resource links provided by NLM:


Further study details as provided by MedImmune LLC:

Primary Outcome Measures:
  • Incidence of solicited symptoms after Dose 1 [ Time Frame: Through Day 28 after each dose ] [ Designated as safety issue: Yes ]
    Solicited symptoms are predefined symptoms or events to be specifically inquired about and assessed daily during the 28-day period after vaccine administration. The solicited symptoms for this study include: fever >100.4°F (>38.0 °C) regardless of route, runny/stuffy nose, cough, drowsiness, loss of appetite/decreased urine output, irritability/Fussiness, oropharyngeal irritation (laryngitis), epistaxis

  • Incidence of solicited symptoms after Dose 2 [ Time Frame: Through Day 28 after each dose ] [ Designated as safety issue: Yes ]
    Solicited symptoms are predefined symptoms or events to be specifically inquired about and assessed daily during the 28-day period after vaccine administration. The solicited symptoms for this study include: fever >100.4°F (>38.0 °C) regardless of route, runny/stuffy nose, cough, drowsiness, loss of appetite/decreased urine output, irritability/Fussiness, oropharyngeal irritation (laryngitis), epistaxis

  • Incidence of solicited symptoms after Dose 3 [ Time Frame: Through Day 28 after each dose ] [ Designated as safety issue: Yes ]
    Solicited symptoms are predefined symptoms or events to be specifically inquired about and assessed daily during the 28-day period after vaccine administration. The solicited symptoms for this study include: fever >100.4°F (>38.0 °C) regardless of route, runny/stuffy nose, cough, drowsiness, loss of appetite/decreased urine output, irritability/Fussiness, oropharyngeal irritation (laryngitis), epistaxis

  • Incidence of adverse events (AEs) after Dose 1 [ Time Frame: Through Day 28 after each dose ] [ Designated as safety issue: Yes ]
    As defined by the ICH Guideline for Good Clinical Practice, an AE is: Any untoward medical occurrence in a participant or clinical investigations subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

  • Incidence of AEs after Dose 2 [ Time Frame: Through Day 28 after each dose ] [ Designated as safety issue: Yes ]
    As defined by the ICH Guideline for Good Clinical Practice, an AE is: Any untoward medical occurrence in a participant or clinical investigations subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

  • Incidence of AEs after Dose 3 [ Time Frame: Through Day 28 after each dose ] [ Designated as safety issue: Yes ]
    As defined by the ICH Guideline for Good Clinical Practice, an AE is: Any untoward medical occurrence in a participant or clinical investigations subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

  • Incidence of medically-attended lower respiratory illnesses (MA-LRIs) after Dose 1 [ Time Frame: Through Day 28 after each dose ] [ Designated as safety issue: Yes ]
    An MA-LRI is defined as a health care provider confirmed diagnosis of any one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, apnea

  • Incidence of MA-LRIs after Dose 2 [ Time Frame: Through Day 28 after each dose ] [ Designated as safety issue: Yes ]
    An MA-LRI is defined as a health care provider confirmed diagnosis of any one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, apnea

  • Incidence of MA-LRIs after Dose 3 [ Time Frame: Through Day 28 after each dose ] [ Designated as safety issue: Yes ]
    An MA-LRI is defined as a health care provider confirmed diagnosis of any one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, apnea

  • Incidence of SAEs [ Time Frame: Administration of Dose 1 (Day 0) through Day 28 post final dose ] [ Designated as safety issue: Yes ]
    An SAE is any adverse event that results in any of the following outcomes: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability or incapacity; congenital anomaly/birth defect (in the offspring of a subject); an important medical event that may not result in death, threaten life or require hospitalization may be considered a serious adverse event when, based upon appropriate medical judgment, it may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above.


Secondary Outcome Measures:
  • Incidence of MEDI-559 shedding [ Time Frame: Day 7-10 after Dose 1, 2, and 3 ] [ Designated as safety issue: No ]
    Number (%) of subjects who shed vaccine-type virus

  • Incidence of MEDI-559 shedding [ Time Frame: Day 12-18 after Dose 1, 2, and 3 ] [ Designated as safety issue: No ]
    Number (%) of subjects who shed vaccine-type virus

  • Incidence of MEDI-559 shedding [ Time Frame: Day 28-34 post Dose 1, 2, and 3 ] [ Designated as safety issue: No ]
    Number (%) of subjects who shed vaccine-type virus

  • Post-vaccination seroresponse against RSV [ Time Frame: Day 28 post final dose ] [ Designated as safety issue: No ]
    Seroresponse is defined as a ≥ 4-fold rise from baseline as measured by microneutralization assay

  • Phenotypic stability of recovered vaccine-type virus [ Time Frame: Day 7-10 post any dose ] [ Designated as safety issue: No ]
    Number (%) of nasal wash samples containing vaccine-type virus that is found to be phenotypically stable

  • Phenotypic stability of recovered vaccine-type virus [ Time Frame: Day 12-18 post any dose ] [ Designated as safety issue: No ]
    Number (%) of nasal wash samples containing vaccine-type virus that is found to be phenotypically stable

  • Phenotypic stability of recovered vaccine-type virus [ Time Frame: Day 28-34 post any dose ] [ Designated as safety issue: No ]
    Number (%) of nasal wash samples containing vaccine-type virus that is found to be phenotypically stable

  • Genotypic stability of recovered vaccine-type virus [ Time Frame: Day 7-10 post any dose ] [ Designated as safety issue: No ]
    Number (%) of nasal wash samples containing vaccine-type virus that is found to be genotypically stable

  • Genotypic stability of recovered vaccine-type virus [ Time Frame: Day 12-18 post any dose ] [ Designated as safety issue: No ]
    Number (%) of nasal wash samples containing vaccine-type virus that is found to be genotypically stable

  • Genotypic stability of recovered vaccine-type virus [ Time Frame: Day 28-34 post any dose ] [ Designated as safety issue: No ]
    Number (%) of nasal wash samples containing vaccine-type virus that is found to be genotypically stable

  • Incidence of MA-LRIs [ Time Frame: Study Day 0 through 365 days post randomization ] [ Designated as safety issue: Yes ]
    Number (%) of subjects with MA-LRIs occurring from Study Day 0 through the end of study

  • Incidence of SAEs [ Time Frame: Study Day 0 post Dose 1 through 365 days post randomization ] [ Designated as safety issue: Yes ]
    Number (%) of subjects with SAEs occurring from Study Day 0 through 365 days post randomization

  • Incidence of significant new medical conditions (SNMCs) [ Time Frame: Study Day 0 post Dose 1 through 365 days post randomization ] [ Designated as safety issue: Yes ]
    Number (%) of subjects with SNMCs from administration of Dose 1 through 365 days post randomization


Enrollment: 116
Study Start Date: October 2008
Study Completion Date: August 2012
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1 MEDI-559
MEDI-559
Biological: MEDI-559
Cohort 1 (5 to <24 months): N=80 MEDI-559 at 10^5 FFU at 0, 2, and 4 months; frozen preparation filled into 0.5 ml luer slip-tip syringes. Each 0.2 ml dose contains 10^5 FFU MEDI-559 in a sucrose phosphate glutamate buffer.
Placebo Comparator: Cohort 1 Placebo
Placebo
Other: Placebo
Cohort 1 (5 to < 24 months); N = 80 placebo at 0, 2, and 4 months; frozen preparation filled into 0.5 ml luer slip-tip syringes. Each 0.2 ml dose contains sucrose phosphate buffer.

Detailed Description:

This is a randomized, double-blind, placebo-controlled, multi-dose, Phase 1/2a multi-center trial to evaluate the safety, tolerability, viral shedding, immunogenicity, and genotypic and phenotypic stability of MEDI-559 in RSV seronegative infants 5 to <24 months of age and in infants 1 to <3 months of age regardless of baseline serostatus. The primary objective of this study is to describe the 28-day post-final dose safety and tolerability of three doses of MEDI-559 at 10^5 FFU when administered to healthy RSV seronegative children 5 to <24 months of age and to healthy infants 1 to <3 months of age regardless of baseline serostatus.

MEDI-559 will be administered at a dose of 10^5 fluorescent focus units (FFU) on a 0, 2, and 4 month schedule to two cohorts of subjects in a step-wise fashion. The target sample size for this study is 320 subjects, with 160 subjects 5 to <24 months of age enrolled into Cohort 1 and 160 subjects 1 to <3 months of age enrolled into Cohort 2. Each cohort will be randomized 1:1 (MEDI-559 to placebo) and stratified by site. Cohort 1 will initiate dosing at 10^5 FFU MEDI-559. Blinded safety data from the first 40 subjects enrolled in Cohort 1 for the 28 days following administration of the first dose of vaccine will be reviewed. If no safety concerns are noted, Cohort 2 will initiate dosing at 10^5 FFU. Enrollment into Cohort 2 will be halted after approximately 40 subjects have been randomized, and blinded safety data will be reviewed through 28 days post Dose 1. If no safety concerns are noted, the remainder of Cohort 2 will be enrolled. All subjects will be followed through 365 days after randomization to ensure that each subject has been followed through an RSV season.

  Eligibility

Ages Eligible for Study:   1 Month to 23 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female whose age on the day of randomization falls within one of the two age cohorts: Cohort 1: 5 to <24 months (reached their 5th month birthday but not yet reached their 2nd year birthday); Cohort 2: 1 to < 3 months (>28 days of age and not yet reached their 3rd month birthday)
  • Cohort 1 only: Subject is seronegative to RSV at screening
  • Subject was the product of normal full term pregnancy (defined as 36-42 weeks gestation)
  • Subject is in general good health
  • Written informed consent and HIPAA authorization (if applicable) obtained from the subject's legal representative
  • Subject's legal representative is willing and able to bring the subject to the study site for evaluation of respiratory illness in accordance with the protocol

Exclusion Criteria:

  • Any fever (≥ 100.4°F [≥ 38.0°C]), regardless of route within 7 days prior to randomization
  • Acute illness (defined as the presence of moderate or severe signs and symptoms) at the time of randomization
  • Moderate or severe nasal congestion that in the investigator's opinion could prevent intranasal delivery of vaccine
  • Cohort 1 only: weight ≤ 5th percentile for age on the day of randomization
  • Cohort 2 only: history of low birth weight (ie, <2500 grams at birth) or weight ≤ 5th percentile for age on the day of randomization
  • Living in the same home or enrolled in the same classroom at day care with infants <6 months of age within 28 days after each dose (only one child per household may be enrolled into the study)
  • Contact with pregnant caregiver within 28 days after each dose
  • Living in a household with someone who is immunocompromised within 28 days after each dose; the subject should also avoid close contact with immunocompromised individuals for at least 28 days after each study vaccine dosing
  • Living in a household with someone who works in the healthcare field and who has direct patient care responsibilities within 28 days after each dose
  • Living in a household with someone who is a day care provider or preschool teacher for children <6 months of age within 28 days after each dose
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00767416

  Show 76 Study Locations
Sponsors and Collaborators
MedImmune LLC
Investigators
Study Director: Joseph Sliman, M.D. MedImmune LLC
  More Information

Additional Information:
No publications provided by MedImmune LLC

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Medical Monitor, MedImmune, LLC
ClinicalTrials.gov Identifier: NCT00767416     History of Changes
Other Study ID Numbers: MI-CP147
Study First Received: October 3, 2008
Last Updated: August 8, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by MedImmune LLC:
respiratory syncytial virus, RSV, pediatric, vaccine

ClinicalTrials.gov processed this record on September 18, 2014